MA45714A - Activateurs de glucokinase et leurs procédés d'utilisation - Google Patents
Activateurs de glucokinase et leurs procédés d'utilisationInfo
- Publication number
- MA45714A MA45714A MA045714A MA45714A MA45714A MA 45714 A MA45714 A MA 45714A MA 045714 A MA045714 A MA 045714A MA 45714 A MA45714 A MA 45714A MA 45714 A MA45714 A MA 45714A
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- glucokinase activators
- glucokinase
- activators
- Prior art date
Links
- 102000030595 Glucokinase Human genes 0.000 title 1
- 108010021582 Glucokinase Proteins 0.000 title 1
- 239000012190 activator Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/657163—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
- C07F9/657181—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom the ring phosphorus atom and, at least, one ring oxygen atom being part of a (thio)phosphonic acid derivative
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662365520P | 2016-07-22 | 2016-07-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA45714A true MA45714A (fr) | 2019-05-29 |
Family
ID=59501613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA045714A MA45714A (fr) | 2016-07-22 | 2017-07-21 | Activateurs de glucokinase et leurs procédés d'utilisation |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10604541B2 (fr) |
| EP (1) | EP3487862A1 (fr) |
| JP (1) | JP7072557B2 (fr) |
| KR (1) | KR102513342B1 (fr) |
| CN (1) | CN109715637B (fr) |
| MA (1) | MA45714A (fr) |
| WO (1) | WO2018017910A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20260020180A (ko) * | 2023-06-06 | 2026-02-10 | 후아 메디슨 (상하이) 엘티디. | 인지 장애 및 신경퇴행성 질병을 위한 글루코키나아제 활성제 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5594113A (en) | 1988-06-23 | 1997-01-14 | Associates Of Cape Cod, Inc. | Endotoxin binding and neutralizing protein and uses thereof |
| US5776983A (en) | 1993-12-21 | 1998-07-07 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
| US5488064A (en) | 1994-05-02 | 1996-01-30 | Bristol-Myers Squibb Company | Benzo 1,3 dioxole derivatives |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| US5491134A (en) | 1994-09-16 | 1996-02-13 | Bristol-Myers Squibb Company | Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives |
| US5541204A (en) | 1994-12-02 | 1996-07-30 | Bristol-Myers Squibb Company | Aryloxypropanolamine β 3 adrenergic agonists |
| US5620997A (en) | 1995-05-31 | 1997-04-15 | Warner-Lambert Company | Isothiazolones |
| AU6966696A (en) | 1995-10-05 | 1997-04-28 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
| US5770615A (en) | 1996-04-04 | 1998-06-23 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| UA57811C2 (uk) | 1997-11-21 | 2003-07-15 | Пфайзер Продактс Інк. | Фармацевтична композиція, що містить інгібітор альдозоредуктази та інгібітор глікогенфосфорилази (варіанти), комплект, який її включає, та способи лікування ссавців зі станом інсулінорезистентності |
| PT1094816E (pt) | 1998-07-06 | 2009-03-10 | Bristol Myers Squibb Co | Sulfonamidas bifenílicas duplamente antagonistas receptores de angiotensina e endotelina |
| US6320050B1 (en) | 1999-03-29 | 2001-11-20 | Hoffmann-La Roche Inc. | Heteroaromatic glucokinase activators |
| US6610846B1 (en) | 1999-03-29 | 2003-08-26 | Hoffman-La Roche Inc. | Heteroaromatic glucokinase activators |
| DE60125734T2 (de) | 2000-03-08 | 2007-10-25 | Metabasis Therapeutics, Inc., La Jolla | Neue aryl fructose-1,6-bisphosphatase inhibitoren |
| EP1465869B1 (fr) | 2001-12-21 | 2013-05-15 | Exelixis Patent Company LLC | Modulateurs de lxr |
| US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
| MY141521A (en) | 2002-12-12 | 2010-05-14 | Hoffmann La Roche | 5-substituted-six-membered heteroaromatic glucokinase activators |
| MXPA05009059A (es) * | 2003-02-26 | 2005-10-19 | Banyu Pharma Co Ltd | Derivados de heteroarilcarbamoilbenceno. |
| WO2005025504A2 (fr) | 2003-09-12 | 2005-03-24 | Kemia, Inc. | Modulateurs de l'activite de la calcitonine et de l'amyline |
| DK2060266T3 (da) | 2004-03-17 | 2011-11-14 | 7Tm Pharma As | Y4-selektiv receptoragonist PP2-36 til terapeutiske indgreb |
| EP1756096B1 (fr) | 2004-05-03 | 2009-08-12 | F.Hoffmann-La Roche Ag | Derives d'indolyle en tant que modulateurs du recepteur x du foie |
| US20080026987A1 (en) | 2004-06-17 | 2008-01-31 | Novo Nordisk A/S | Use of Liver-Selective Glucokinase Activators |
| NZ575512A (en) | 2005-07-09 | 2009-11-27 | Astrazeneca Ab | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes |
| US7910747B2 (en) | 2006-07-06 | 2011-03-22 | Bristol-Myers Squibb Company | Phosphonate and phosphinate pyrazolylamide glucokinase activators |
| CN101490064B (zh) * | 2006-07-06 | 2012-10-10 | 百时美施贵宝公司 | 新颖葡萄糖激酶活化剂及其使用方法 |
| US7888504B2 (en) | 2006-07-06 | 2011-02-15 | Bristol-Myers Squibb Company | Glucokinase activators and methods of using same |
| GB0619325D0 (en) | 2006-09-30 | 2006-11-08 | Univ Strathclyde | New compounds |
| US20080221128A1 (en) | 2007-03-07 | 2008-09-11 | Christian Gege | Metalloprotease inhibitors containing a squaramide moiety |
| EP2170852A1 (fr) | 2007-06-11 | 2010-04-07 | Bristol-Myers Squibb Company | Activateurs de la glucokinase de type phénylamide à substitution 1,3 hydroxy |
| JP2010534722A (ja) | 2007-07-27 | 2010-11-11 | ブリストル−マイヤーズ スクイブ カンパニー | 新規グルコキナーゼ活性化薬およびその使用方法 |
| WO2009023718A2 (fr) * | 2007-08-13 | 2009-02-19 | Metabasis Therapeutics, Inc. | Nouveaux activateurs de glucokinase |
| AR068540A1 (es) | 2007-09-28 | 2009-11-18 | Merck & Co Inc | Metodos de produccion de un derivado de pirazol-3-il-benzamida. |
| US7741327B2 (en) | 2008-04-16 | 2010-06-22 | Hoffmann-La Roche Inc. | Pyrrolidinone glucokinase activators |
| KR101258331B1 (ko) | 2008-09-11 | 2013-04-26 | 화이자 인코포레이티드 | 헤테로아릴 아미드 유도체 및 글루코키나제 활성화제로서의 그의 용도 |
| US20110294853A1 (en) | 2008-09-12 | 2011-12-01 | Benjamin Pelcman | Bis Aromatic Compounds for Use in the Treatment of Inflammation |
| WO2010107610A1 (fr) * | 2009-03-17 | 2010-09-23 | Merck Sharp & Dohme Corp. | Méthode de traitement du diabète et des états pathologiques correspondants par thérapie combinatoire et compositions contenant de tels composés |
| US20110021570A1 (en) | 2009-07-23 | 2011-01-27 | Nancy-Ellen Haynes | Pyridone glucokinase activators |
| EP2558461B1 (fr) * | 2010-04-14 | 2015-12-02 | Bristol-Myers Squibb Company | Nouveaux activateurs de la glucokinase et méthodes d'utilisation desdits activateurs |
| EP2582709B1 (fr) | 2010-06-18 | 2018-01-24 | Sanofi | Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| JP2013544787A (ja) | 2010-10-13 | 2013-12-19 | タケダ カリフォルニア インコーポレイテッド | アザインダゾール誘導体の調製方法 |
| WO2013037390A1 (fr) | 2011-09-12 | 2013-03-21 | Sanofi | Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase |
| EP2760862B1 (fr) | 2011-09-27 | 2015-10-21 | Sanofi | Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique utilisés comme inhibiteurs de kinase |
| ES2760266T3 (es) | 2014-09-09 | 2020-05-13 | Bristol Myers Squibb Co | Moduladores de GPR120 de ácido fenil-(aza)cicloalquil carboxílico |
-
2017
- 2017-07-21 MA MA045714A patent/MA45714A/fr unknown
- 2017-07-21 KR KR1020197004835A patent/KR102513342B1/ko active Active
- 2017-07-21 WO PCT/US2017/043199 patent/WO2018017910A1/fr not_active Ceased
- 2017-07-21 US US16/318,173 patent/US10604541B2/en active Active
- 2017-07-21 JP JP2019503225A patent/JP7072557B2/ja active Active
- 2017-07-21 CN CN201780057682.1A patent/CN109715637B/zh active Active
- 2017-07-21 EP EP17746324.7A patent/EP3487862A1/fr not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US10604541B2 (en) | 2020-03-31 |
| JP2019523253A (ja) | 2019-08-22 |
| KR20190033571A (ko) | 2019-03-29 |
| CN109715637A (zh) | 2019-05-03 |
| US20190233449A1 (en) | 2019-08-01 |
| EP3487862A1 (fr) | 2019-05-29 |
| CN109715637B (zh) | 2022-04-05 |
| WO2018017910A1 (fr) | 2018-01-25 |
| KR102513342B1 (ko) | 2023-03-22 |
| JP7072557B2 (ja) | 2022-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3436048A4 (fr) | Néoantigènes et leurs procédés d'utilisation | |
| EP3684364A4 (fr) | Pyridazinones et leurs procédés d'utilisation | |
| EP3510040A4 (fr) | Inhibiteurs d'éctonucléotidase et leurs procédés d'utilisation | |
| EP3390624A4 (fr) | Polypeptides de modification ciblée modifiés et leurs procédés d'utilisation | |
| EP3298168A4 (fr) | Agents réducteurs stabilisés et leurs procédés d'utilisation | |
| MA46566A (fr) | Oxystérols et leurs procédés d'utilisation | |
| MA44490A (fr) | Adhésifs biocompatibles et leurs procédés d'utilisation | |
| MA46565A (fr) | Oxystérols et leurs procédés d'utilisation | |
| EP3504213A4 (fr) | Composés amino-pyrrolopyrimidinone et leurs procédés d'utilisation | |
| EP3429635A4 (fr) | Composés anti-crispr et leurs procédés d'utilisation | |
| EP3416634A4 (fr) | Agents immunomodulateurs et leurs procédés d'utilisation | |
| MA55097A (fr) | Oxystérols et leurs procédés d'utilisation | |
| EP3319612A4 (fr) | Oxystérols et leurs procédés d'utilisation | |
| EP3319610A4 (fr) | Oxystérols et leurs procédés d'utilisation | |
| EP3377612A4 (fr) | Expression fonctionnelle de monooxygénases et procédés d'utilisation | |
| MA47849A (fr) | Anticorps anti-gitr et leurs procédés d'utilisation | |
| EP3394065A4 (fr) | Tétrahydropyranyl-amino-pyrrolopyrimidinone et procédés d'utilisation associés | |
| EP3436030A4 (fr) | Récepteurs chimériques et leurs procédés d'utilisation | |
| EP3303634A4 (fr) | Variants de cas9 et procédés d'utilisation associés | |
| EP3368538A4 (fr) | Inhibiteurs de la kinase wee 1 et leurs procédés de fabrication et d'utilisation | |
| EP3303435A4 (fr) | Hydrofluoroléfines et procédés d'utilisation associés | |
| EP3352774A4 (fr) | Compositions de flavonoïdes et procédés d'utilisation | |
| MA53355A (fr) | Anticorps anti-ctla-4 et leurs procédés d'utilisation | |
| EP3307762A4 (fr) | Variants de cas9 rapporteurs et leurs procédés d'utilisation | |
| EP3435956A4 (fr) | Compositions photo-stabilisées et leurs procédés d'utilisation |